Glucose Metabolism Effects of Vitamin D Supplementation in Prediabetes

NCT ID: NCT01479933

Last Updated: 2013-03-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

73 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vitamin D deficiency is widespread throughout the world, and the deficiency has been associated with several chronic diseases, such as cardiovascular diseases and diabetes. In Nordic countries, like in Finland, there is a particular variation in vitamin D status, and during wintertime, when there is no exposure to ultraviolet-B light from the sun, serum concentrations of vitamin D decrease substantially. In Finland, some 40% of middle-aged men and one third of women also have some degree of impairment of glucose metabolism.

The purpose of this trial is to investigate the effects of two different daily doses of vitamin D on glucose metabolism in men 60 years of age or older and who are vitamin D deficient, have a high body mass index and at least two characteristics of cardio-metabolic syndrome.

Altogether 102 subjects with low serum calcidiol (\<60 nmol/L) will be recruited and randomized to one of the three groups: 1) 40 µg/d vitamin D3, 2) 80 µg/d vitamin D3 or 3) placebo. The supplementation period will last for 6 months from September 2011 to March 2012.

The main hypotheses of the trial are: (1.) Vitamin D supplementation will improve glucose and insulin metabolism in people with a low baseline vitamin D status, in a dose-dependent manner. (2.) Vitamin D supplementation will have an effect on the expression of genes involved in glucose and insulin metabolism and inflammation. (3.) Vitamin D supplementation will have an effect on epigenetic changes in key genes participating in vitamin D metabolism.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prediabetic State Overweight Obese

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vitamin D 40

Vitamin D3 40 micrograms (1600 IU) per day

Group Type EXPERIMENTAL

Vitamin D3

Intervention Type DIETARY_SUPPLEMENT

Vitamin D3 40 micrograms (1600 IU) per day

Vitamin D 80

Vitamin D3 80 micrograms (3200 IU) per day

Group Type EXPERIMENTAL

Vitamin D 80

Intervention Type DIETARY_SUPPLEMENT

Vitamin D3 80 micrograms (3200 IU) per day

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Inactive placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vitamin D3

Vitamin D3 40 micrograms (1600 IU) per day

Intervention Type DIETARY_SUPPLEMENT

Placebo

Inactive placebo

Intervention Type DIETARY_SUPPLEMENT

Vitamin D 80

Vitamin D3 80 micrograms (3200 IU) per day

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 60 years or older
* Serum calcidiol \<75 nmol/L
* Body mass index 25-35 kg/m2
* Impaired fasting glucose or impaired glucose tolerance (fasting glucose 5.6-7.0 mmol/L or 2h oral glucose tolerance test glucose 7.8-11.0 mmol/L)

Exclusion Criteria

* Any chronic disease and condition, which may hamper to follow the intervention protocol (such as alcohol abuse)
* Any chronic disease or therapy which may mask or interact with the investigated effects (such as diabetes or systemic corticosteroid therapy)
* Any disease or state that raises a vitamin D related safety concern (such as chronic liver, thyroid or kidney disease, hypercalcemia, sarcoidosis or other granulomatous diseases such as active chronic tuberculosis or Wegener's granulomatosis)
* Use of supplements yielding vitamin D over 20 µg/d and unwillingness to discontinue the use.
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Academy of Finland

OTHER

Sponsor Role collaborator

Juho Vainio Foundation

OTHER

Sponsor Role collaborator

Finnish Foundation for Cardiovascular Research

OTHER

Sponsor Role collaborator

Diabetes Research Foundation, Finland

OTHER

Sponsor Role collaborator

University of Eastern Finland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Tomi-Pekka Tuomainen

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Tomi-Pekka Tuomainen, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Eastern Finland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Eastern Finland, Kuopio Campus

Kuopio, Kuopio, Finland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Finland

References

Explore related publications, articles, or registry entries linked to this study.

Ryynanen J, Neme A, Tuomainen TP, Virtanen JK, Voutilainen S, Nurmi T, de Mello VD, Uusitupa M, Carlberg C. Changes in vitamin D target gene expression in adipose tissue monitor the vitamin D response of human individuals. Mol Nutr Food Res. 2014 Oct;58(10):2036-45. doi: 10.1002/mnfr.201400291. Epub 2014 Jul 28.

Reference Type DERIVED
PMID: 24975273 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.uef.fi

University of Eastern Finland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VitDmet

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Finnish Vitamin D Trial (FIND)
NCT01463813 COMPLETED NA
Vitamin D and Type 2 Diabetes Study
NCT01942694 COMPLETED NA
Vitamin D for the Prevention of Diabetes Type 2
NCT00685594 COMPLETED PHASE2/PHASE3